Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multiregion Sequencing of Localized Prostate Cancer

ABSTRACT: Multiregion Sequencing of Localized Prostate Cancer

PROVIDER: PRJNA530801 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Multiregion Sequencing of Localized Prostate Cancer

Project description:Multiregion Sequencing of Localized Prostate Cancer

| PRJNA412429 | ENA

Epigenomic alterations in localized and advanced prostate cancer

Project description:Here we used Illumina NGS for high-throughput profiling of the DNA methylome in seven human benign prostate tissues, seven human primary prostate cancer and six human castration resistant prostate cancer patient samples. These data were used to profile the CpG cytosine methylation pattern at single base resolution in each sample and to determine differentially methylated cytosines and regions among samples. Enhanced Reduced Representation Bisulfite Sequencing (ERRBS, MspI,150M-bM-^@M-^S400 bp size fractions) of 20 human prostate tissues (benign prostate tissues, localized and metastatic prostate cancer)

2013-07-03 | E-GEOD-41701 | biostudies-arrayexpress

Whole Exome Sequencing of Localized Prostate Cancer Patients

Project description:We performed whole-exome sequencing on localized prostate cancer patients to validate tumor content as part of a single-cell RNA sequencing study of localized prostate cancer patients.

| EGAS00001005685 | EGA

Genomic hallmarks of localized, non-indolent prostate cancer

Project description:Genomic hallmarks of localized, non-indolent prostate cancer

| PRJNA327861 | ENA

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Project description:Widespread and Functional RNA Circularization in Localized Prostate Cancer.

| PRJNA450081 | ENA

Expression profile of localized primary prostate cancer samples and the matched normal tissues

Project description:To identify new oncogenic drivers in prostate cancer, we performed transcriptome analysis of localized primary prostate cancer samples and the matched normal tissues.

2021-05-01 | GSE114740 | GEO

The Methylome-Genome Interactions in Localized Prostate Cancer Define Disease Aggression

Project description:Localized prostate cancer exhibits profound genomic, pathologic, and clinical heterogeneity, and current clinical prognostic factors do not accurately distinguish aggressive from indolent disease for an individual man. We and others have demonstrated that aberrant DNA methylation may be an important driver of aggressive disease. Herein, we analyze the tumor methylomes of 619 localized prostate cancers and assess the interactions between methylation and somatic tumor genomic profiles. We identify three distinct methylation subtypes, including a hypermethylation subtype which is associated with early biochemical recurrence. DNA methylation and gene copy number status synergistically regulate mRNA abundance, and aberrant methylation is strongly associated with common prostate cancer driver aberrations, including mutation density, and with altered RNA abundance profiles. Finally, we identify a set of multivariate methylation biomarkers that are prognostic of rapid biochemical recurrence. Taken together, our data provide the first comprehensive assessment of the interplay between somatic molecular phenotypes and aberrant DNA methylation in localized, non-indolent prostate cancer, and suggest that integrated genome-epigenome analyses may accurately identify men at risk for adverse clinical outcomes in this patient cohort.

2019-06-30 | GSE107298 | GEO

Genomic hallmarks of localized, non-indolent prostate cancer

Project description:Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries. Local hypermutation events were frequent, and correlated with specific genomic profiles. Numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberrations outperformed well-described prognostic biomarkers. We suggest that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates.

2017-01-10 | GSE84042 | GEO

Genomic hallmarks of localized, non-indolent prostate cancer

2017-01-10 | GSE83917 | GEO

The Methylome-Genome Interactions in Localized Prostate Cancer Define Disease Aggression

Project description:The Methylome-Genome Interactions in Localized Prostate Cancer Define Disease Aggression

| PRJNA419651 | ENA